The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas
Hematological Oncology - United Kingdom
doi 10.1002/hon.38_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley